BRMS1表达预测手术切除肺腺癌的未来转移并与不良预后相关
本研究纳入1030例完全切除的肺腺癌患者,通过组织微阵列免疫组化评估瘤内BRMS1表达强度。低BRMS1表达(39%)与更高病理T分期、更大肿瘤、淋巴管/血管侵犯及不良组织学亚型相关,且为OS(HR=1.35,95%CI 1.10-1.65,p=0.004)和DFS(HR=1.27,95%CI 1.05-1.54,p=0.012)更差的独立预测因子。
要点
- 低BRMS1表达与更高病理T分期、更大肿瘤及淋巴管/血管侵犯相关。
- 低BRMS1表达是OS和DFS更差的独立预测因子。
- 基于BRMS1等指标的列线图对OS和DFS预测性能良好。
核心结论
- 在手术切除的肺腺癌患者中,瘤内BRMS1低表达者OS和DFS显著更差,BRMS1为独立预后生物标志物。
研究设计与样本
- 回顾性队列研究,纳入1030例完全切除且组织可评估的肺腺癌患者,构建组织微阵列行BRMS1免疫组化染色并评分。
主要发现
- BRMS1高表达632例(61%),低表达398例(39%)。
- 低BRMS1表达与更高病理T分期(p=0.001)、更大肿瘤(p≤0.0001)、淋巴管侵犯(p=0.032)、血管侵犯(p=0.001)、肺腺癌组织学亚型(p=0.001)及中/高级别结构分级(p=0.003)相关。
- 低BRMS1表达为OS更差的独立预测因子(HR=1.35,95%CI 1.10-1.65,p=0.004)。
- 低BRMS1表达为DFS更差的独立预测因子(HR=1.27,95%CI 1.05-1.54,p=0.012)。
- OS和DFS列线图在区分度和校准度方面显示优良的预测性能。
临床怎么用
- BRMS1免疫组化表达水平可作为手术切除肺腺癌的预后评估指标,低表达提示复发和死亡风险更高,或有助于辅助治疗决策与随访强度分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Expression of breast cancer metastasis suppressor 1 gene (BRMS1) is decreased in NSCLC cells and tumors. We hypothesized that intratumoral breast cancer metastasis suppressor 1 (BRMS1) expression is associated with lung adenocarcinoma (LUAD) histologic subtypes and overall survival (OS) and disease-free survival (DFS) in patients undergoing resection for early-stage LUAD. METHODS: Patients (N = 1030) who underwent complete resection for LUAD with tissue available for histologic evaluation were identified. Tissue microarrays were constructed, and immunostaining was performed and scored for intensity of BRMS1 expression. OS and DFS were estimated (by the Kaplan-Meier method) and compared between groups (by the log-rank test), stratified by stage. Hazard ratios (HRs) for hazard of death and recurrence were estimated using univariable and multivariable Cox proportional hazards models. OS and DFS nomograms were created, and model performance was examined. RESULTS: Intratumoral BRMS1 expression was high in 632 patients (61%) and low in 398 (39%). Low BRMS1 expression was associated with higher pathologic T stage (p = 0.001), larger tumor size (p ≤ 0.0001), greater lymphatic (p = 0.032) and vascular (p = 0.001) invasion, LUAD histologic subtype (p = 0.001), and intermediate and high architectural tumor grade (p = 0.003). Low BRMS1 expression was an independent predictor of worse OS (HR = 1.35, 95% confidence interval: 1.10-1.65, p = 0.004) and DFS (HR = 1.27, 95% confidence interval: 1.05-1.54, p = 0.012). OS and DFS nomograms showed excellent predictive performance based on discrimination and calibration. CONCLUSIONS: Among patients with surgically resected LUAD, OS and DFS were significantly worse in cases with low intratumoral BRMS1 expression. Our findings suggest that BRMS1 is an independent biomarker with prognostic significance in surgically resected LUAD.
引用
- Bucciarelli PR, Tan KS, Chudgar NP, et al. BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis. J Thorac Oncol. 2017. PMID: 29097253. doi:10.1016/j.jtho.2017.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。